ECM
Endurant Capital Management Portfolio holdings
AUM
$17.4M
This Quarter Return
-1.89%
1 Year Return
+4.95%
3 Year Return
+16.8%
5 Year Return
+58.39%
10 Year Return
–
AUM
$329M
AUM Growth
+$329M
(-9.6%)
Cap. Flow
-$74.6M
Cap. Flow
% of AUM
-22.66%
Top 10 Holdings %
Top 10 Hldgs %
54.35%
Holding
72
New
13
Increased
16
Reduced
20
Closed
21
Top Buys
| 1 |
Humana
HUM
|
$11M |
| 2 |
Johnson & Johnson
JNJ
|
$10.5M |
| 3 |
AbbVie
ABBV
|
$10.2M |
| 4 |
SI-BONE Inc
SIBN
|
$9.23M |
| 5 |
Hologic
HOLX
|
$6.59M |
Top Sells
| 1 |
Thermo Fisher Scientific
TMO
|
$15M |
| 2 |
Labcorp
LH
|
$12.4M |
| 3 |
Icon
ICLR
|
$8.57M |
| 4 |
Haemonetics
HAE
|
$7.86M |
| 5 |
EAR
Eargo, Inc. Common Stock
EAR
|
$7.72M |
Sector Composition
| 1 | Healthcare | 80.38% |
| 2 | Industrials | 1.89% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
AbbVie
ABBV
$372B
| $19.5M | 4.43% | 180,429 +94,915 | +111% | +$10.2M |
|
|
2
Humana
HUM
$36.5B
| $17.1M | 3.9% | 44,022 +28,231 | +179% | +$11M |
|
|
3
Johnson & Johnson
JNJ
$427B
| $15.8M | 3.61% | 98,077 +65,079 | +197% | +$10.5M |
|
|
4
Hologic
HOLX
$14.9B
| $14.8M | 3.36% | 200,119 +89,279 | +81% | +$6.59M |
|
5
Bio-Rad Laboratories Class A
BIO
$8.06B
| $13.6M | 3.1% | 18,272 +6,452 | +55% | +$4.81M |
|
6
Bristol-Myers Squibb
BMY
$96B
| $12.5M | 2.85% | 211,821 +110,740 | +110% | +$6.55M |
|
|
7
Icon
ICLR
$13.8B
| $12.2M | 2.79% | 46,720 -32,695 | -41% | -$8.57M |
|
8
Tenet Healthcare
THC
$16.3B
| $11.9M | 2.71% | 179,288 -38,603 | -18% | -$2.56M |
|
|
9
SI-BONE Inc
SIBN
$719M
| $10.1M | 2.3% | 471,214 +431,059 | +1,073% | +$9.23M |
|
|
SYNH
10
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
| $8.12M | 1.85% | 92,761 -37,477 | -29% | -$3.28M |
|
11
Veracyte
VCYT
$2.39B
| $7.81M | 1.78% | 168,211 +28,000 | +20% | +$1.3M |
|
12
Cigna
CI
$80.3B
| $7.24M | 1.65% | 36,188 -35,668 | -50% | -$7.14M |
|
13
Elutia
ELUT
$96.7M
| $6.63M | 1.51% | 952,610 +79,451 | +9% | +$553K |
|
14
Avantor
AVTR
$9.18B
| $6.62M | 1.51% | 161,963 +9,568 | +6% | +$391K |
|
15
McKesson
MCK
$85.4B
| $6.49M | 1.48% | +32,551 | New | +$6.49M |
|
16
Owens & Minor
OMI
$378M
| $6.38M | 1.45% | 203,784 +136,795 | +204% | +$4.28M |
|
|
RCM
17
DELISTED
R1 RCM Inc. Common Stock
RCM
| $6.23M | 1.42% | 282,911 -265,965 | -48% | -$5.85M |
|
18
AptarGroup
ATR
$9.18B
| $6.11M | 1.39% | +51,191 | New | +$6.11M |
|
19
Ocular Therapeutix
OCUL
$2.12B
| $6.1M | 1.39% | 610,401 +39,431 | +7% | +$394K |
|
|
20
Labcorp
LH
$23.1B
| $5.3M | 1.21% | 18,829 -44,090 | -70% | -$12.4M |
|
|
ADAP
21
Adaptimmune Therapeutics
ADAP
$15.6M
| $4.74M | 1.08% | 917,488 -621,947 | -40% | -$3.22M |
|
22
AdaptHealth
AHCO
$1.28B
| $4.54M | 1.03% | +194,886 | New | +$4.54M |
|
23
Insmed
INSM
$28.8B
| $4.4M | 1% | 159,903 -100,411 | -39% | -$2.77M |
|
24
Cartesian Therapeutics
RNAC
$261M
| $4.25M | 0.97% | 1,021,501 +94,566 | +10% | +$393K |
|
|
MTEM
25
DELISTED
Molecular Templates, Inc.
MTEM
| $4.12M | 0.94% | 613,630 -134,383 | -18% | -$902K |
|